Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience


Triplet-drug regimen bortezomib–thalidomide–dexamethasone (VTD) and bortezomib–lenalidomide–dexamethasone (VRD) are considered as standard of care induction prior autologous stem-cell transplantation (ASCT) in myeloma. In addition to improve response rate, induction therapy should preserve an adequate stem-cell collection. In the present retrospective study, we analyzed stem-cell collection in 325 newly diagnosed myeloma patients who received either VTD or VRD induction before ASCT. Stem-cell mobilization consisted of intravenous cyclophosphamide plus G-CSF. Plerixafor was administered preemptively to rescue mobilization. In comparison with VTD, VRD induction was associated with a more frequent use of plerixafor (19.3% versus 5.4%, p = 0.004) and with an increased number of apheresis to reach adequate collection (>2 apheresis required in 42.3% versus 30.2%, p = 0.05). Moreover, more patients experienced collection failure in the VRD group (6% versus 1.8%, p = 0.004). The median number of CD34-positive cells (×106/kg) was lower in the VRD group: 8.5 versus 9.3 (p = 0.05) in the VTD group. The vast majority of patients underwent ASCT (93% versus 98%, in VRD and VTD group, respectively). These data highlight the need of optimal stem-cell collection strategy, especially in the context of tandem transplantation and incorporation of anti-CD38 monoclonal antibody into induction.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Impact of VTD or VRD induction on stem-cell collection.


  1. 1.

    Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    CAS  Article  Google Scholar 

  2. 2.

    Moreau P, Touzeau C, Vij R, Goldsmith SR, Rosko AE. Newly diagnosed myeloma in 2020. Am Soc Clin Oncol Educ Book. 2020;40:1–15.

    PubMed  Google Scholar 

  3. 3.

    Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589–96.

    Article  Google Scholar 

  4. 4.

    Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127:2569–74.

    CAS  Article  Google Scholar 

  5. 5.

    Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard M-J, Hernández MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma. Blood. 2019.

  6. 6.

    Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–61.

    CAS  Article  Google Scholar 

  7. 7.

    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–548.

    Article  Google Scholar 

  8. 8.

    Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–9.

    CAS  Article  Google Scholar 

  9. 9.

    Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43:619–25.

    CAS  Article  Google Scholar 

  10. 10.

    Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904–12.

    CAS  Article  Google Scholar 

  11. 11.

    DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.

    CAS  Article  Google Scholar 

  12. 12.

    Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013;28:359–67.

    PubMed  Google Scholar 

  13. 13.

    Sánchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant. 2015;50:34–39.

    Article  Google Scholar 

  14. 14.

    Van de Wyngaert Z, Nerich V, Fouquet G, Chrétien M-L, Caillot D, Azar N, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplant. 2020.

  15. 15.

    Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, et al. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost analysis. Transfus Apher Sci. 2020:102819.

  16. 16.

    Skerget M, Skopec B, Sever M. VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization. Acta Haematologica Polonica. 2020;51:42–46.

    Article  Google Scholar 

  17. 17.

    Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–42.

    CAS  Article  Google Scholar 

  18. 18.

    Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008;22:1282–4.

    CAS  Article  Google Scholar 

  19. 19.

    Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:718–23.

    Article  Google Scholar 

  20. 20.

    Dosani T, Covut F, Pinto R, Kim B-G, Ali N, Beck R, et al. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leuk Lymphoma. 2019;60:2199–206.

    CAS  Article  Google Scholar 

  21. 21.

    Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, et al. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a Phase 2 Clinical Trial. JAMA Oncol. 2018;4:1781–3.

    Article  Google Scholar 

  22. 22.

    Bal S, Landau HJ, Shah GL, Scordo M, Dahi P, Lahoud OB, et al. Stem cell mobilization and autograft minimal residual disease negativity 1 with novel induction regimens in multiple myeloma. Biol Blood Marrow Transplant. 2020.

  23. 23.

    Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.

    CAS  Article  Google Scholar 

  24. 24.

    Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood.

  25. 25.

    Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020.

  26. 26.

    Weisel K, Asemissen AM, Besemer B, Haenel M, Blau IW, Goerner M. et al. Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. JCO. 2020;38:8508.

    Article  Google Scholar 

  27. 27.

    Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel K, et al. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant. 2011;46:59–63.

    CAS  Article  Google Scholar 

Download references


CT, PM, and SLG, are members of Site de Recherche Intégrée sur le Cancer (SIRIC) ILIAD, (INCA-DGOS-Inserm_12558).

Author information




VL, CF, and CT, designed the study. VL, CF, CA, and CT, collected data. BT, performed statistical analysis. PD, performed stem-cell harvesting. CT, and VL, wrote the manuscript. All authors treated patients and critically reviewed the manuscript, and gave final approval.

Corresponding author

Correspondence to Cyrille Touzeau.

Ethics declarations

Conflict of interest

CT and PM are advisory board member and received honoraria from Sanofi.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Laurent, V., Fronteau, C., Antier, C. et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant (2020).

Download citation